Researchers in Brazil found a protein that can be used to indicate which patients in the early stages of nonsmall cell lung cancer (NSCLC) have a good prognosis and which do not. High levels of this protein correlate with resistance to certain anticancer drugs, especially cisplatin and carboplatin. This new finding may help doctors decide on the best course of action for each NSCLC patient, which may greatly impact survival rates.